Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL

In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:Approved and Investigational Targeted Therapeutics for CLL  Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell LymphomaBispecific Antibodies and Other Investigational Targeted Agents for LymphomasTreatment for Older Patients With Hodgkin LymphomaPresenters:Jeremy S. Abramson, MD, MMScAssociate Professor  Department of Medicine  Harvard Medical School  Director, Center for Lymphoma  Massachusetts General Hospital  Boston, MassachusettsContent based on an online CME program supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology.Link to full program:https://bit.ly/3tyQ9nG    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.